- Home
- ANTX vs NBP Comparison
ANTX vs NBP Comparison
Compare ANTX & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANTX | NBP |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.9M | 149.2M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ANTX | NBP |
|---|---|---|
| Price | $3.59 | $1.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $9.00 | $9.00 |
| AVG Volume (30 Days) | 306.3K | ★ 672.5K |
| Earning Date | 11-11-2026 | 08-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $1.26 |
| 52 Week High | $7.19 | $5.19 |
Technical Indicators
Market Signals| Indicator | ANTX | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 21.92 | 33.75 |
| Support Level | $2.87 | N/A |
| Resistance Level | $5.21 | $1.44 |
| Average True Range (ATR) | 0.40 | 0.05 |
| MACD | -0.17 | 0.00 |
| Stochastic Oscillator | 2.34 | 25.00 |
Price Performance
Historical ComparisonAbout ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.